Clinuvel Pharmaceuticals Ltd is a specialty biopharmaceutical company that develops and commercializes treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. The company's core business revolves around its proprietary melanocortin technology, specifically afamelanotide. Its flagship product, SCENESSE, is an injectable implant approved in the US, Europe, Israel, and Australia for the prevention of phototoxicity (severe pain and burns) in adult patients with erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder. Clinuvel employs a direct distribution model, selling SCENESSE directly to specialized treatment centers, which has enabled the company to maintain high profit margins and achieve consistent profitability. Beyond EPP, Clinuvel is expanding its clinical pipeline to evaluate afamelanotide for other indications, including vitiligo, variegate porphyria (VP), xeroderma pigmentosum (XP), and arterial ischaemic stroke. The company is also developing additional melanocortin-based products, such as PRÉNUMBRA and NEURACTHEL, and is advancing a line of topical PhotoCosmetic products for broader consumer markets. Geographically, the company generates the majority of its revenue from the US and European markets.
Clinuvel Pharmaceuticals Ltd is a specialty biopharmaceutical company that develops and commercializes treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. The company's core business revolves around its proprietary melanocortin technology, specifically afamelanotide. Its flagship product, SCENESSE, is an injectable implant approved in the US, Europe, Israel, and Australia for the prevention of phototoxicity (severe pain and burns) in adult patients with erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder. Clinuvel employs a direct distribution model, selling SCENESSE directly to specialized treatment centers, which has enabled the company to maintain high profit margins and achieve consistent profitability. Beyond EPP, Clinuvel is expanding its clinical pipeline to evaluate afamelanotide for other indications, including vitiligo, variegate porphyria (VP), xeroderma pigmentosum (XP), and arterial ischaemic stroke. The company is also developing additional melanocortin-based products, such as PRÉNUMBRA and NEURACTHEL, and is advancing a line of topical PhotoCosmetic products for broader consumer markets. Geographically, the company generates the majority of its revenue from the US and European markets.